Specializing in gene therapy for rare skin diseases, this biotech firm has gained attention for its proprietary redosable gene therapy platform. Investors monitor KRYS for its pipeline targeting conditions like dystrophic epidermolysis bullosa and its commercial execution of approved therapies.
1 member of Congress has disclosed 1 trade in Krystal Biotech, Inc. (KRYS), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |